ReviewClinical cancer research : an official journal of the American Association for Cancer Research2020
Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- RAS signaling at the crossroads of radioresistance and tumor immunity.Journal for immunotherapy of cancer · 2026Review
- Distinct immune responses to proton and photon radiotherapy: implications for anti-PD-L1 combination therapy in colorectal cancer.Journal of translational medicine · 2025Article
- Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003-2023).Frontiers in oncology · 2025Article
- Review
- Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe.International journal of nanomedicine · 2024Article
- Radiotherapy in bone sarcoma: the quest for better treatment option.BMC cancer · 2023Review
- High incidence combination of multiple primary malignant tumors of the digestive system.World journal of gastroenterology · 2022Article
- Review
- Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy.International journal of molecular sciences · 2022Article
- Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report.Frontiers in immunology · 2022Article
- How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Tumour motion management in lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Chronic Inflammation and Radiation-Induced Cystitis: Molecular Background and Therapeutic Perspectives.Cells · 2020Review
- Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies.Frontiers in oncology · 2020Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
Newer technical improvements in radiation oncology have been rapidly implemented in recent decades, allowing an improved therapeutic ratio. The development of strategies using local and systemic treatments concurrently, mainly targeted therapies, has however plateaued. Targeted molecular compounds and immunotherapy are increasingly being incorporated as the new standard of care for a wide array of cancers. A better understanding of possible prior methodology issues is therefore required and should be integrated into upcoming early clinical trials including individualized radiotherapy-drug combinations. The outcome of clinical trials is influenced by the validity of the preclinical proofs of concept, the impact on normal tissue, the robustness of biomarkers and the quality of the delivery of radiation. Herein, key methodological aspects are discussed with the aim of optimizing the design and implementation of future precision drug-radiotherapy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.